Impact of HBV serological status on HIV virological efficacy of two‐drug antiretroviral regimens: A retrospective observational study on virologically suppressed people with HIV switching to lamivudine/dolutegravir

Documenti analoghi

• Effectiveness and tolerability of dolutegravir/lamivudine in virologically suppressed people with HIV at 96 weeks in a multicentre cohort
  di: Inés Suárez‐García, et al.
  Pubblicazione: (2025)
• Real‐world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV‐1 aged over 50 years who are virologically suppressed
  di: C. Piñeiro, et al.
  Pubblicazione: (2024)
• Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies
  di: C. Katlama, et al.
  Pubblicazione: (2024)
• Clinical management of detectable viraemia during CAB / RPV long‐acting therapy: Are really PIs the only exit strategies?
  di: P. F. Salvo, et al.
  Pubblicazione: (2026)
• Association between markers of hepatitis B virus infection and risk of virological rebound in people with HIV receiving antiretroviral therapy
  di: Vincenzo Malagnino, et al.
  Pubblicazione: (2024)